Compare COE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | VRCA |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 88.0M |
| IPO Year | 2015 | 2018 |
| Metric | COE | VRCA |
|---|---|---|
| Price | $20.00 | $5.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 13.6K | ★ 30.4K |
| Earning Date | 06-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $14.66 | $3.28 |
| 52 Week High | $56.13 | $9.82 |
| Indicator | COE | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 44.53 |
| Support Level | $15.16 | $4.25 |
| Resistance Level | $28.40 | $6.29 |
| Average True Range (ATR) | 1.17 | 0.43 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 83.26 | 48.72 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.